-transparent.png){kind=logo}
OBJECTIVE We studied the possible interaction between itraconazole, a potent inhibitor of CYP3A, and zopiclone, a short-acting hypnotic. METHODS A double-blind, randomized, two-phase crossover design was used. Ten healthy young subjects received daily either 200 mg itraconazole or placebo for 4 days. On day 4 they ingested a single 7.5-mg oral dose of zopiclone. Plasma concentrations of zopiclone and itraconazole were determined and pharmacodynamic responses were measured up to 17 h. RESULTS Itraconazole significantly increased the Cmax of zopiclone from 49 to 63 ng.ml-1. The t 1/2 of zopiclone was prolonged from 5.0 to 7.0 h. The AUC(0-inifinity) of zopiclone was increased from 415 to 719 ng.ml-1 h by itraconazole. No statistically significant differences were observed in the pharmacodynamic responses between the groups. CONCLUSIONS Itraconazole has a statistically significant pharmacokinetic interaction with zopiclone but this is only of limited clinical importance, at least in young adults.
K M Jalava, and
K T Olkkola, and
P J Neuvonen
October 1994,
British journal of clinical pharmacology,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
April 1998,
European journal of clinical pharmacology,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
February 2003,
Swiss medical weekly,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
April 2000,
European journal of clinical pharmacology,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
January 1996,
Fundamental & clinical pharmacology,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
October 1998,
Psychopharmacology,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
November 2003,
European journal of clinical pharmacology,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
April 1996,
Therapeutic drug monitoring,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
June 2002,
Therapeutic drug monitoring,
K M Jalava, and
K T Olkkola, and
P J Neuvonen
September 1995,
British journal of clinical pharmacology,
